Registry assessing PSMA PET outcomes in prostate cancer
PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer
This study is testing if PSMA PET imaging can help doctors better understand the outcomes for men with prostate cancer compared to traditional methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University Hospital, Essen Academic / other |
| Locations | 1 site (Essen) |
| Trial ID | NCT06320223 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognostic value of Prostate-Specific Membrane Antigen (PSMA) PET imaging in patients with prostate cancer. It will compare the outcomes of PSMA PET with established clinical prognostic scores across various stages of the disease. The study will include adult patients who have undergone PSMA PET for staging or re-staging and have at least three years of follow-up data available. The findings could enhance risk assessment and management strategies for prostate cancer patients.
Who should consider this trial
Good fit: Ideal candidates are adult patients with biopsy-proven prostate cancer who have undergone PSMA PET imaging for staging or re-staging.
Not a fit: Patients with neuroendocrine prostate cancer or those with metastasized malignancies other than prostate cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve prognostic accuracy and treatment guidance for patients with prostate cancer.
How similar studies have performed: Other studies have shown promising results with PSMA PET imaging in prostate cancer, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer.
Where this trial is running
Essen
- University Hospital Essen — Essen, Germany (Recruiting)
Study contacts
- Principal investigator: Wolfgang P Fendler, M.D. — University Hospital, Essen
- Study coordinator: Wolfgang P Fendler, M.D.
- Email: redcap@ikim.nrw
- Phone: +492017232032
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.